Compare CRCT & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRCT | DBVT |
|---|---|---|
| Founded | 1969 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.1M | 948.8M |
| IPO Year | 2021 | 2014 |
| Metric | CRCT | DBVT |
|---|---|---|
| Price | $5.84 | $13.91 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $3.00 | ★ $32.04 |
| AVG Volume (30 Days) | ★ 784.9K | 382.0K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 22.20% | N/A |
| EPS Growth | ★ 20.69 | 10.26 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $708,780,000.00 | $5,636,000.00 |
| Revenue This Year | $0.08 | $35.04 |
| Revenue Next Year | $0.98 | $2,360.78 |
| P/E Ratio | $21.00 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $3.74 | $8.80 |
| 52 Week High | $6.93 | $26.19 |
| Indicator | CRCT | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 68.86 | 43.29 |
| Support Level | $4.03 | $12.75 |
| Resistance Level | $6.27 | $14.68 |
| Average True Range (ATR) | 0.32 | 0.70 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 77.23 | 52.24 |
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.